Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge Advises H&M on Acquisition of Cheap Monday
Mandate

Vinge Advises H&M on Acquisition of Cheap Monday

March 11, 2008

Vinge advises H&M in connection to the acquisition of 60 % of Fabric Scandinavia AB through Adam Friberg, Lars Karlsson, Örjan Andersson and Linda Friberg. Fabric Scandinavia AB runs the chain of boutiques Weekday and Monki and the group also designs and sells fashion for brands such as Cheap Monday. The transaction is conditioned by the approval of competition authorities. The transaction includes an option to acquire the shares that remain in Fabric Scandinavia AB within a period of three to five years.

Malin Leffler, Jonas Bergström, Joacim Rydergård, Kristoffer Nordman, Daniel Unger, Niclas Bergström and Johan Cederblad made up Vinge’s team. 

Related

Vinge has advised Morrow Bank AB (publ) in conjunction with the acquisition of MedMera Bank AB

 Vinge has advised Morrow Bank AB (publ) in conjunction with the acquisition of all shares in MedMera Bank AB from Kooperativa Förbundet for a total consideration of SEK 1,960 million. The transaction positions Morrow Bank as a leading Nordic platform in consumer finance with combined gross loans of SEK 28.2 billion.
March 24, 2026

Vinge advises NEWS, a portfolio company of Litorina, in connection with the sale of Skandinavisk Kommunalteknik, FANN VA-Teknik and Alunda Polyeten to Wienerberger AG

 Vinge advises Northern Environmental and Water Solutions AB (“NEWS”), a portfolio company of Litorina, in connection with the sale of the operating subsidiaries Skandinavisk Kommunalteknik, FANN VA-Teknik and Alunda Polyeten to Wienerberger AG (Vienna Stock Exchange: WIE). The transaction is expected to be completed in Q2 2026.
March 24, 2026

Vinge has advised Hansa Biopharma in connection with entering into a financing agreement

 Vinge has advised Hansa Biopharma AB (publ), a commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life-altering treatments for patients with rare immunological conditions, listed on Nasdaq Stockholm, in connection with a U.S. convertible note purchase agreement comprising USD 30 million aggregate principal amount of unsecured convertible senior notes.
March 23, 2026